Unlocking the Potential of SUCLG1: A Drug Target and Biomarker forSUCCINATE-COA LIGASE ALPHA SUBUNIT

Target Name: SUCLG1

NCBI ID: G8802

SUCLG1

Unlocking the Potential of SUCLG1: A Drug Target and Biomarker forSUCCINATE-COA LIGASE ALPHA SUBUNIT

SUCLG1 (succinate-CoA ligase alpha subunit), a 23-kDa protein, is a key enzyme in the citric acid cycle (CAC), a central metabolic pathway that generates energy in the form of ATP through the production of Adenosine A1 (A1), NAD+, FAD, and GTP. This enzyme plays a crucial role in the biosynthesis of aromatic amino acids, such as tryptophan and tyrosine, which are essential for various cellular processes. The dysfunction of SUCLG1 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. As a result, targeting this enzyme has the potential to develop new treatments for a variety of diseases.

Drug Target and Biomarker

SUCLG1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. The inhibition of SUCLG1 has been shown to enhance the efficacy of various therapeutic approaches in diseases such as cancer, neurodegenerative disorders, and metabolic disorders.

One of the key advantages of targeting SUCLG1 is its potential to reduce the production of reactive oxygen species (ROS), which can cause oxidative stress and contribute to the development of various diseases. ROS production is a result of the dysfunction of various antioxidant enzymes, including SUCLG1. By inhibiting SUCLG1 activity, researchers have shown that they can reduce the production of ROS and improve the cellular redox state, leading to a reduction in cellular damage.

Another potential mechanism by which SUCLG1 can contribute to disease development is its role in the production of aromatic amino acids, which are essential for the development and maintenance of various cellular processes, including cell growth, differentiation, and inflammation. The dysfunction of SUCLG1 has been implicated in the production of certain aromatic amino acids, such as tryptophan and tyrosine, which can lead to the formation of harmful compounds, such as N-methyl-D-aspartate (NMDA), which has been linked to the development of neurodegenerative disorders.

In addition to its potential role in the production of aromatic amino acids, SUCLG1 has also been shown to play a crucial role in the regulation of cellular processes that are essential for human health. For example, SUCLG1 has been shown to regulate the activity of several enzymes involved in the production of essential nutrients, including vitamins B2 and B6. The dysfunction of these enzymes has been implicated in the development of various diseases, including scurvy and homocystinuria.

Expression and Measurement

SUCLG1 expression has been studied extensively both in cell culture and in vivo, and several studies have shown that the levels of this enzyme are highly elevated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. For example, studies have shown that the expression of SUCLG1 is highly elevated in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its expression, the function of SUCLG1 has also been evaluated through various experiments. For example, research has shown that the inhibition of SUCLG1 has the potential to enhance the sensitivity of cancer cells to chemotherapy and radiation treatments. Additionally, studies have shown that the inhibition of SUCLG1 has the potential to reduce the production of ROS, which can contribute to the development of neurodegenerative disorders.

Potential Therapeutic Strategies

The inhibition of SUCLG1 has the potential to enhance the efficacy of various therapeutic approaches in diseases such as cancer, neurodegenerative disorders, and metabolic disorders. Several studies have shown that the inhibition of SUCLG1 has the potential to reduce the production of ROS, which can

Protein Name: Succinate-CoA Ligase GDP/ADP-forming Subunit Alpha

Functions: Succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of either ATP or GTP and thus represents the only step of substrate-level phosphorylation in the TCA. The alpha subunit of the enzyme binds the substrates coenzyme A and phosphate, while succinate binding and specificity for either ATP or GTP is provided by different beta subunits

The "SUCLG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUCLG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets